Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS.
Mitochondrial dysfunction in central nervous system white matter disorders.
Fingolimod (Gilenya) eligibility extended by NHS England
Astrocyte CCL2 sustains immune cell infiltration in chronic experimental autoimmune encephalomyelitis.
Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker.
Retinal nerve fibre layer and brain grey substance as early prognostic factors for disability in multiple sclerosis.
Multiple sclerosis: Natalizumab reduces cortical pathology in relapsing-remitting multiple sclerosis.
Structural Brain MR Imaging Changes Associated with Obsessive-Compulsive Disorder in Patients with Multiple Sclerosis.
Mast cells and inflammation.
Color blindness among multiple sclerosis patients in Isfahan.
Immunomodulatory activity of interferon-beta.
Observational Study Assessing Demographic, Economic and Clinical Factors Associated with Access and Utilization of Health Care Services of Patients with Multiple Sclerosis under Treatment with Interferon Beta-1b (EXTAVIA).
Multimodal Quantitative MR Imaging of the Thalamus in Multiple Sclerosis and Neuromyelitis Optica.
Interferon-β1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors.
Betaferon efficiency indicators in the treatment of relapsing remitting form of multiple sclerosis.
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.
Emotional and neutral verbal memory impairment in Multiple Sclerosis.
Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.
Increased determinism in brain electrical activity occurs in association with multiple sclerosis.
Re-expression of N-cadherin in remyelinating lesions of experimental inflammatory demyelination.
Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain.
Rituximab combination therapy in relapsing multiple sclerosis.
Imaging multiple sclerosis and other neurodegenerative diseases.
Saffold Virus Type 3 (SAFV-3) Persists in HeLa Cells.
MicroRNA dysregulation in multiple sclerosis.
Pages
« first
‹ previous
…
261
262
263
264
265
266
267
268
269
…
next ›
last »